Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
The antiproliferative effects of BSJ-4-116 (10–10,000 nM; 72 hours) on Kelly CDK12C1039F are strong [1]. Irrespective of the cell line's mutation status, BSJ-4-116 (50 nM; 6-24 hours) lowers CDK12 protein levels [1]. The T-ALL cells (Jurkat and MOLT-4 cells) are sensitive to PARP inhibition and their growth is inhibited by BSJ-4-116 [1]. Through poly(adenylation), BSJ-4-116 controls the expression of DDR genes. The mutation CDK12C1039F is overcome by BSJ-4-116. As a result of acquired point mutations in the target protein, BSJ-4-116 is the first instance of resistance to a bivalent degradation molecule [1].
|
---|---|
Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Parental Kelly and CDK12C1039F Cell Tested Concentrations: 10-10000 nM Incubation Duration: 72 hrs (hours) Experimental Results: The anti-proliferative activity of BSJ-4-116 is independent of mutation status and the degrader compounds exhibit improved GR50 (Growth rate inhibition of Kelly CDK12C1039F cells compared to the parental cell line) value. Western Blot Analysis[1] Cell Types: Parental and Kelly cells expressing CDK12C1039F (KellyCDK12CF) Tested Concentrations: 50 nM Incubation Duration: 6-24 hrs (hours) Experimental Results: Result in the same level of reduction in CDK12 protein levels regardless of mutational status of the cell line. |
References |
[1]. Jiang B, et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol. 2021;17(6):675-683.
|
Molecular Formula |
C40H49CLN8O8SEXACTMASS
|
---|---|
Molecular Weight |
837.3839
|
Exact Mass |
836.31
|
Elemental Analysis |
C, 57.37; H, 5.90; Cl, 4.23; N, 13.38; O, 15.28; S, 3.83
|
CAS # |
2519823-34-6
|
Appearance |
Solid powder
|
SMILES |
ClC1=C([H])N=C(N=C1N([H])C1=C([H])C([H])=C([H])C([H])=C1S(C([H])(C([H])([H])[H])C([H])([H])[H])(=O)=O)N([H])[C@]1([H])C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(C([H])([H])OC2=C([H])C([H])=C([H])C3C(N(C(C=32)=O)C2([H])C(N([H])C(C([H])([H])C2([H])[H])=O)=O)=O)=O)C1([H])[H]
|
Chemical Name |
Acetamide, N-[7-[(3R)-3-[[5-chloro-4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-1-piperidinyl]heptyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]-
|
Synonyms |
BSJ4-116BSJ-4-116 BSJ 4-116BSJ4116 BSJ-4116BSJ 4116
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~250 mg/mL (~298.55 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1942 mL | 5.9710 mL | 11.9420 mL | |
5 mM | 0.2388 mL | 1.1942 mL | 2.3884 mL | |
10 mM | 0.1194 mL | 0.5971 mL | 1.1942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.